Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cidara Therapeutics ( (CDTX) ) has issued an announcement.
On September 24, 2025, Cidara Therapeutics announced an update to its Phase 3 trial plan for CD388 following discussions with the FDA. The trial will now include a broader population, potentially increasing eligible patients in the U.S. from 50 million to over 100 million, and will begin enrollment by the end of September 2025, six months earlier than initially planned.
The most recent analyst rating on (CDTX) stock is a Buy with a $123.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.
Spark’s Take on CDTX Stock
According to Spark, TipRanks’ AI Analyst, CDTX is a Neutral.
Cidara Therapeutics’ overall stock score is primarily influenced by its challenging financial performance, which is offset by strong technical momentum and positive earnings call sentiment. The company’s recent corporate events and promising clinical trial results provide a supportive backdrop, but the lack of profitability and reliance on external financing remain significant concerns.
To see Spark’s full report on CDTX stock, click here.
More about Cidara Therapeutics
Cidara Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of long-acting therapeutics to improve the standard of care for patients facing serious diseases. The company is primarily engaged in creating innovative treatments for infectious diseases and oncology.
Average Trading Volume: 731,648
Technical Sentiment Signal: Buy
Current Market Cap: $2.25B
See more data about CDTX stock on TipRanks’ Stock Analysis page.